The renowned Cold Spring Harbor Laboratory (CSHL) in Long Island, New York, a bastion basic biomedical research, made a major foray into the more applied development of the drug. Today, the laboratory and the Shore LIJ Northern Health System, a local hospital system, announced a new alliance and an investment of over $ 0 million to move basic discoveries into clinical cancer .
The alliance does not mean that CSHL moves away from basic research, said Bruce Stillman, CSHL CEO and President. "Our discovery science has placed us as one of the leading research institutes in the world," and "I want to keep it at that level," he said. But the lab also wants to transform these discoveries into drugs. He found an "ideal marriage" with North Shore-LIJ, which has 16,000 new cases of cancer each year in the New York area and wanted to expand its academic clinical research, he said. "This will provide a significant amount of funds to the translational research on cancer we have done on a tight budget," said Stillman.
Failure to CSHL nonprofit, which turns 125 this year , a $ 145 million budget and 0 researchers and technicians who study cancer, neuroscience, plant biology and quantitative biology. the laboratory has long had a National cancer Institute-designated cancer where center work using genomics, RNAi screens and mouse models gave drug targets against the major cancer. But until now, the laboratory has relied largely on pharmaceutical companies to develop these findings into treatments. "this will take another level "with the researchers of the covenant of target validation, protocol development, and conduct of clinical trials early stage, Stillman said.
However, "we" are not claiming that we will become a full-service pharmaceutical company, "said Stillman. The company plans to use outside contractors research organizations for measures such as screening small molecules and conduct of medical chemistry.
North Shore-LIJ will recruit a new head for its cancer institute, which will also be on the faculty of CSHL. The lab also plans to hire more clinician scientists like David Tuveson, a researcher recruited pancreatic cancer 4 years ago from Research UK Cambridge Cancer Institute in the United Kingdom, who is now deputy director of CSHL cancer Center. Tuveson and Stillman say the new company aims to emulate the Cancer Research Institute in London, where basic and clinical research have worked together on the early development of drugs such as PARP inhibitors that target cancers with defects in DNA repair, and abiraterone, used to treat prostate cancer. "The idea is to take our scientific approach in early stage clinical studies," an area that is not well supported either by finance companies or federal drug, Tuveson said.
The both partners are not disclosing the source of the initial $ 0 million. But Stillman notes that donors and private foundations contributed $ 22 million for preclinical therapeutic development center that CSHL began building in 2013.
Stillman said the new company will not compromise basic research CSHL. Despite over a decade of flat budgets to national Institutes of health, the federal funding is CSHL and the laboratory is two thirds of the way a goal of raising $ 250 million largely for its endowment to support basic research. the laboratory has not plans to reduce its meetings and courses program that welcomes gatherings such as the Biology of genomes, the one of the most important meetings in the field of genomics. "The identity of Cold Spring Harbor will not change," said Stillman
* Correction, April 2, 1:25 p.m. :. previous affiliation David Tuveson was corrected
0 Komentar